AIIMS: Covaxin effective for 9-12 months, no serious side-effects so far
Published By : Sourabha Parida | February 13, 2021 7:34 PM
Share
New Delhi, Feb 13: Mathematical calculations indicate that Covaxin may provide immunity against Covid-19 for 9 to 12 months, and there may be a booster shot after this period elapses, Y.K. Gupta, the President of AIIMS Bhopal and Jammu, told IANS. Stressing on the safety and effectiveness of Covaxin, Gupta, former Dean (Academics), and ex-Head, Department of Pharmacology, AIIMS, New Delhi, said that no death has been reported so far due to Covaxin, nor has there been any case of major side-effects, adding that more clarity will emerge by March end when data from Phase 3 trials will be available to establish the efficacy of Covaxin. The approval for Covaxin, the homegrown vaccine developed by Bharat Biotech, had faced unrelenting criticism, especially when it was administered to scores of healthcare workers during Phase 1 of the vaccination drive. The critics have badgered Covaxin's approval in the absence of Phase 3 trial data. Speaking to IANS, Gupta said, "These are not scientifically correct claims. Covaxin was approved for emergency use and the data from Phase 1 and Phase 2 trials, and the ongoing Phase 3 trials, suggest that it is safe and effective, and by March-end tentatively, the data from Phase 3 trials will be available to establish its efficacy." When queried on the safety of Covaxin and people developing side-effects after its administration, Gupta said: "The vaccine is being given to lakhs of people, and there are hardly any serious side-effects. Rather there are only minor side-effects, whuihg indicate the effectiveness of the vaccine. No death has been caused by Covaxin so far." Commenting on India's vaccine technology in the backdrop the new mutant coronavirus strain reported in a few countries, Gupta said: "The Indian vaccine technology with minor tweaking has the potential to address these new strains." Addressing the attack on the efficacy of Covaxin by many scientists globally, Yadav said they have made irresponsible comments. "It is better to take Covaxin than having irreversible damage to lungs due to Covid-19. By March end, we will have more real-life evidence and there will be more clarity. If Phase 3 trials give good results, it will be a matter of pride... No adverse event has been reported so far," said Gupta. He added that the regulator approves a drug if its efficacy is found to be over 50 per cent, which has been the case for Covaxin, and emphasised that different hypothesis and extrapolation suggest that it will be effective. "There should not be any vaccine hesitancy," Gupta said. (IANS)
Prameya English Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
SUM Hospital launches free Cy-Tb test
Odisha health department set for joint drive against water & vector borne diseases
Determined to saw off every drug cartel and protect our youth: Amit Shah
COVID-19 vaccines not linked to surge in heart attack deaths: Health Ministry
Odisha: Youth lead the way in ‘Menstrual Health Awareness’ at Berhampur University
AIIMS Bhubaneswar ranked 2nd best emerging medical college in India
Health Minister reviews Dengue, Malaria, Diarrhea, and Jaundice, orders for proactive measures
Diarrhea outbreak in Odisha under control: Health Minister
Food Safety Crackdown in Bhuban: Stalls Sealed and Fined Amid Public Health Crisis
International Yoga Day 2025: History and significance
OMC Launches Major Sickle Cell Anemia Awareness Drive in Odisha's Mining Belts
Diarrhea outbreak in Jajpur triggers panic; Six hotels sealed
Odisha: Expert teams deployed to tackle Diarrhoea outbreak in three districts
Odisha: Health Minister reviews Diarrhoea outbreak, urges rapid action
Odisha battles Diarrhoea outbreak; Minister Suraj Suryavanshi reviews situation in Jajpur
AIIMS Bhubaneswar to be accorded Centre of Excellence Status for Sickle Cell Disease Management
"From Research to Practice": GSICON 2025 Aims to Revolutionize Geriatric Medicine in India
Odisha Govt intensifies diarrhea prevention measures across five districts
Orissa High Court halts Asst. Prof Recruitment at AHPGIC Cuttack citing irregularity
Odisha: Diarrhoea outbreak in Cuttack, 64 infected, one dead